New hope for Tough-to-Treat blood cancer: phase 3 trial launched
NCT ID NCT07579234
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called F182112 against standard treatments in 261 adults with multiple myeloma that has returned or stopped responding to prior therapies. The goal is to see if the new drug can delay cancer growth longer than usual care. Participants must have already tried at least one drug from three key classes, including anti-CD38 therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists test CAR-T cells made inside the body to fight Hard-to-Treat myeloma
- New antibody drug aims to outsmart Treatment-Resistant myeloma
- New Three-Drug cocktail aims to tackle Hard-to-Treat multiple myeloma
- Double-Barreled CAR-T cells take aim at Hard-to-Treat myeloma
- Double-Barreled CAR-T attack on Hard-to-Treat myeloma
- New antibody drug tested for tough blood cancers – but trial stopped early